Skip to main content
KLTO
NASDAQ Life Sciences

Klotho Neurosciences Proposes Reverse Stock Split to Avoid Nasdaq Delisting and Seeks Significant Equity Plan Expansion

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$0.338
Mkt Cap
$24.517M
52W Low
$0.114
52W High
$3.91
Market data snapshot near publication time

summarizeSummary

Klotho Neurosciences is proposing a reverse stock split with a broad ratio range (1-for-2 to 1-for-50) to address a Nasdaq deficiency for failing to meet the $1.00 minimum bid price. This action, while crucial for maintaining its listing, often signals underlying financial challenges and is typically viewed negatively by the market. Concurrently, the company seeks to increase its equity incentive plan by 8.3 million shares, which represents approximately 13.3% potential dilution of current outstanding shares. The projected 50% annual burn rate for equity compensation further underscores a heavy reliance on equity, which could lead to substantial dilution for existing shareholders. Investors should closely monitor the effectiveness of the reverse split in sustaining the stock price and the ongoing dilutive impact of the expanded equity plan.


check_boxKey Events

  • Reverse Stock Split Proposed

    Shareholders will vote on a reverse stock split with a ratio between 1-for-2 and 1-for-50, aimed at increasing the per-share price to meet Nasdaq's $1.00 minimum bid price requirement.

  • Equity Incentive Plan Expansion

    The company proposes to increase the shares reserved for its 2024 Equity Incentive Plan by 8,331,874, bringing the total to 10,000,000 shares, representing approximately 13.3% potential dilution of current outstanding shares.

  • Nasdaq Delisting Threat

    Klotho Neurosciences received a delinquency notification from Nasdaq on September 19, 2025, for non-compliance with the minimum bid price requirement, making the reverse split critical for continued listing.

  • High Projected Burn Rate

    The company projects an annual burn rate of 50% for its equity compensation, indicating a rapid rate of share issuance from the incentive plan.


auto_awesomeAnalysis

Klotho Neurosciences is proposing a reverse stock split with a broad ratio range (1-for-2 to 1-for-50) to address a Nasdaq deficiency for failing to meet the $1.00 minimum bid price. This action, while crucial for maintaining its listing, often signals underlying financial challenges and is typically viewed negatively by the market. Concurrently, the company seeks to increase its equity incentive plan by 8.3 million shares, which represents approximately 13.3% potential dilution of current outstanding shares. The projected 50% annual burn rate for equity compensation further underscores a heavy reliance on equity, which could lead to substantial dilution for existing shareholders. Investors should closely monitor the effectiveness of the reverse split in sustaining the stock price and the ongoing dilutive impact of the expanded equity plan.

この提出時点で、KLTOは$0.34で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$2451.7万でした。 52週の取引レンジは$0.11から$3.91でした。 この提出書類はネガティブの市場センチメント、重要度スコア8/10と評価されました。

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed KLTO - Latest Insights

KLTO
Mar 12, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
10
KLTO
Mar 10, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
10
KLTO
Mar 04, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
10
KLTO
Mar 04, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
10
KLTO
Mar 02, 2026, 5:03 PM EST
Filing Type: 8-K
Importance Score:
9
KLTO
Feb 24, 2026, 6:12 AM EST
Filing Type: 424B3
Importance Score:
9
KLTO
Feb 23, 2026, 6:36 PM EST
Filing Type: 8-K
Importance Score:
9
KLTO
Feb 17, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8
KLTO
Jan 23, 2026, 5:23 PM EST
Filing Type: DEF 14A
Importance Score:
8
KLTO
Jan 12, 2026, 3:48 PM EST
Filing Type: PRE 14A
Importance Score:
8